phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide has been researched along with brimonidine tartrate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chieng, B; Christie, MJ; Connor, M | 1 |
| García-Barrado, MJ; Iglesias-Osma, MC; Martín, M; Moratinos, J; Rodríguez, R | 1 |
2 other study(ies) available for phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide and brimonidine tartrate
| Article | Year |
|---|---|
The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
Topics: Animals; Brimonidine Tartrate; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Methionine; Enkephalins; In Vitro Techniques; Kinetics; Locus Coeruleus; Male; Naloxone; Narcotics; Neurons; Nociceptin; Opioid Peptides; Peptide Fragments; Peptides; Potassium; Potassium Channels; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Somatostatin | 1996 |
Role of mu-opioid receptors in insulin release in the presence of inhibitory and excitatory secretagogues.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Clonidine; Drug Interactions; Female; Glyburide; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Naloxone; Quinoxalines; Receptors, Opioid, mu; Somatostatin | 2002 |